Dyne Therapeutics, Inc.
About
19.33USD+0.77 +4.15%
Closed • Updated at 02:40 GMT+00:00Market Cap$3.20B
Volume1.50M
Beta0.96
RSI59.61
Dyne Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 26 2026
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 20 2026
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
May 11 2026
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Apr 27 2026
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
Apr 1 2026
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Recent Videos
Dyne Filed in Duchenne. Motion Is Not Proof.
May 27, 2026
Duchenne Muscular Dystrophy Advances
Apr 04, 2026
Trending in Neuroscience: Phase 3 HARMONIA and more
Mar 19, 2026
Neuroscience Update – 18 Mar 2026: Phase 3 HARMONIA in DM1, Roche ApoE4 CE Mark and More
Mar 18, 2026
Community Chat
Ask AI
Try asking